Sub-Q Bionics Raises $1.5 Million to Advance Lymphedema Treatment
Sub-Q Bionics has successfully raised $1.5 million in a pre-seed funding round aimed at advancing its innovative solution for lymphedema treatment. The funding round was led by Mayo Clinic, with participation from Yeda Research and Development Company and the Israel Innovation Authority.
Innovative Approach to Lymphedema Treatment
The company is developing a bionic lymph node technology that acts as a subcutaneous implant. This device is designed to manage lymphatic fluid automatically, aiming to alleviate symptoms such as swelling and pain while improving mobility and quality of life for patients. Lymphedema, a condition affecting millions globally, particularly cancer survivors, has limited effective treatment options.
"Our mission at Sub-Q Bionics is to meaningfully improve the standard of care for patients living with lymphedema," said Jordan Pollack, CEO of Sub-Q Bionics.
Strategic Use of Funds
The funds will be directed towards accelerating product development, achieving pre-clinical milestones, and establishing regulatory and commercial strategies. This financial boost will enable Sub-Q Bionics to refine its implantable device further and prepare for a seed funding round expected to open in the second quarter of 2026.
Collaborative Efforts
Mayo Clinic, as the lead investor, will collaborate with Sub-Q Bionics on research and development efforts. Additionally, Yeda Research and Development Company supports the venture through its Weizmann Innovation Nest platform, which aids in translating scientific discoveries into commercial-ready products.
Looking Ahead
Sub-Q Bionics aims to provide an advanced solution that offers greater freedom of movement for lymphedema patients compared to traditional therapies. With this fresh injection of capital, the company is well-positioned to push forward its development agenda and bring its promising technology closer to market availability.